Annual Reports in Medicinal Chemistry

Part 1 Central nervous system diseases, D.W. Robertson: recent advances in migraine therapy, T. Branchek and J.E. Audia; Alzheimer's disease - recent advances on the amyloid hypothesis, V. John et al; obesity - leptin-neuropeptide Y interactions in the control of body weight, D.R. Gehlert and M. Heiman; melatonin receptor ligands and their potential clinical applications, C.D. Mahle et al; corticotrophin-releasing hormone (CRH) receptors and the discovery of selective non-peptide CRH1 antagonists, P.J. Gilligan et al; recent advances in neurokinin receptor antagonists, S.G. Mills. Part 2 Cardiovascular and pulmonary diseases, A.M. Doherty: endothelin inhibitors, X.-M. Cheng et al; antithrombotics/serine proteases, W.C. Ripka and G.P. Vlasuk; leukotriene modulators as therapeutic agents in asthma and other inflammatory diseases, R.L. Bell et al; emerging opportunities in the treatment of atherosclerosis, C.M. Hayward and M.J. Bamberger. Part 3 Cancer and infectious diseases, J.J. Plattner: new approaches and agents to overcome bacterial resistance, J.M. Domagala and J.P. Sanchez; bacterial genomics and the search for novel antibiotics, L. Katz et al; resistance to antiretroviral drug therapy, A. Molla and W.E. Kohlbrenner; non-HIV antiviral agents, S.H. Krawczyk and N. Bischofberger; recent advances in antifungal agents, P.A. Lartey and C.M. Moehle; angiogenesis inhibitors, D. Powell et al; chemical inhibitors of cyclin-dependent kinases, K.G. Coleman et al. Part 4 Immunology, endocrinology and metabolic diseases, W.K. Hagmann: T lymphocyte potassium channel blockers, J.C. Kath et al; male contraception, D.W. Combs; new dermatological agents for the treatment of psoriasis, S. Nagpal and R.A.S. Chandraratna; selective cyclooxygenase-2 inhibitors, P. Prasit and D. Riendeau; growth hormone secretagogues, R.P. Nargund and L.H.T. Van der Ploeg. Part 5 Topics in biology, W.W. Wong: novel gene switches for the regulation of gene expression; agents that block TNF-I synthesis or activity, R.A. Black et al; nuclear orphan receptors - scientific progress and therapeutic opportunities, D.W. Robertson et al. Part 6 Topics in drug design and discovery, G.L. Trainor: discovery and identification of lead compounds from combinational mixtures, B.A. Beutal; electrospray mass spectrometric characterization of adducts between therapeutic agents and proteins, C. Fenselau; nonpeptide agonists for peptide receptors - lessons from ligands, E.E. Sugg; natural products research and pharmaceuticals in the 1990s, S.K. Wrigley and M.I. Chicarelli-Robinson; inhibition of cytochrome P-450 and implications in drug development, J.H. Lin and A.Y.H. Lu. Part 7 Trends and perspectives, J.A. Bristol: to market, to market - 1996, P. Galatsis.